Page Options
>> >>view
Akeso's independently-developed drug approved for marketing
2025-03-19

Penpulimab (trade name: 安尼可®), the only differentiated PD-1 monoclonal antibody independently developed by Zhongshan-based company Akeso, has been approved for marketing by the National Medical Products Administration (NMPA) for the first-line treatment of recurrent or metastatic nasopharyngeal cancer (NPC) in combination with chemotherapy.



0319-4.png



This is the fourth indication for Penpulimab, signifying its full-stage coverage of NPC treatment from the first to the third line. It provides patients with a full-course immunotherapy option.


Penpulimab has also been approved for the first-line treatment of locally advanced or metastatic squamous NSCLC (non-small cell lung cancer) and the treatment of relapsed or refractory classical Hodgkin's lymphoma after at least second-line systemic therapy.


Related News: Zhongshan entrepreneur makes China's 100 power businesswomen list


The 2025 Forbes China's 100 Power Businesswomen list was recently unveiled. Michelle Xia, founder, chairwoman, president and CEO of Akeso, made the list.


Michelle Xiais an expert in molecular biology and antibody drug development. She established Akeso at the National Health Technology Park in Zhongshan in 2012.

Close】 【Print
ICP Registration Number: 粤ICP备 11005604号
Police Registration Number: 44200002442868
Website ID: 4420000052
Sponsored by:  Office of Zhongshan Municipal People's Government
Technical Support:   Information Center of Zhongshan
Without written authorization from  Zhongshan Municipal People’s Government, the content of the site shall not be republished or used in any form.
About Us | Site Map| Privacy Statement| Contact us